48Hour Discovery Inc. is an Alberta-based company providing services in ligand discovery with an unprecedented turnaround time at a manageable cost. Founded in February 2017, our core business is rooted in our proprietary molecular discovery platform emanating from the expertise and IP generated from the Derda Research Group as part of the Alberta Glycomics Centre at the University of Alberta (U of A). The company provides rapid ligand discovery services for any target using our portfolio of genetically-encoded molecules, mining technology, and a standardized discovery protocol. In 2020 the company launched an internal drug development program focussing on gastrointestinal and COVID targets. The company currently has peptide discovery projects with a number of global pharmaceutical companies. We use genetically-encoded phage displayed peptides or peptide-derived libraries to discover ligands for your target. From a library of more than a billion molecules occupying the medium-sized chemical space we ensure our molecules to occupy a “sweet spot†in protein-ligand recognition, which otherwise is hard to access by canonical small molecule drugs and biological (antibody-based) therapeutics. Currently we operate with four different types of in-house encoded libraries. We guarantee the quality and the diversity of each of our libraries for screening services.